Are Poppers (alkyl nitrites) Legal in Georgia? (2026)

Instrument

Dangerous drugs: Salvinorin A

Source

https://www.legis.ga.gov/api/legislation/document/20092010/106178

Retrieved

2026-10-31

Fingerprint

75fddf2cc6284156

SECTION 1.

Article 3 of Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to

dangerous drugs, is amended in subsection (b) of Code Section 16-13-71, relating to the

definition of dangerous drug, by adding a new paragraph to read as follows:

"(851.02)  Salvinorin A;"

SECTION 2.

Said article is further amended in Code Section 16-13-72, relating to sale, distribution, or

possession of dangerous drugs, by adding a new paragraph to read as follows:

"(4.3)  Possession, planting, cultivation, growing, or harvesting of Salvia divinorum or

Salvia divinorum A strictly for aesthetic, landscaping, or decorative purposes;"

Instrument

O.C.G.A. 16-13-25 (Schedule I): 2025-2026 amending bills only

Source

https://www.legis.ga.gov/api/legislation/document/20252026/242800

Retrieved

2026-10-08

Fingerprint

9aca7ce7e83f4f83

LC 65 0071 House Bill 1329 By: Representatives Stephens of the 164th and Newton of the 127th A BILL TO BE ENTITLED AN ACT To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to provide for certain provisions relating to Schedule I controlled substances; to provide for certain provisions relating to the definition of dangerous drugs; to provide for related matters; to provide for an effective date; to repeal conflicting laws; and for other purposes. BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA: SECTION 1. Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (E) of paragraph (16) as follows: “(E) By substitution at the 5-position or 6-position with a nitro, alkyl, halide, cyano, or acetyl group or primary amine;” SECTION 2. Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding new paragraphs to subsection (b) to read as follows: H. B. 1329 -1- LC 65 0071 "(1.5) Aceclidine;" “(12.7) Acoltremon;” "(17.2) Aficamten;" “(68.45) Atrasentan;” "(69.21) Avutometinib;" "(91.71) Berahyaluronidase alfa-pmph;" "(106.4) Brensocatib;" "(196.3) Clesrovimab-cfor;" "(240.97) Datopotamab deruxtecan-dlnk;" “(243.4) Defactinib;” “(244.7) Delgocitinib;” "(248.5) Depemokimab-ulaa;" “(316.6) Donidalorsen;” “(317.15) Dordaviprone;” "(318.7) Doxecitine;" "(320.5) Doxribtimine;" “(331.0513) Elamipretide;” "(331.0555) Elinzanetant;" "(379.8) Etripamil;" "(386.95) Fitusiran;" "(411.9) Garadacimab-gxii;" “(414.4) Gepotidacin;” "(466.7) Imlunestrant;" "(513.75) Lerodalcibep-liga;" “(523.5) Linvoseltamab-gcpt;” “(619.15) Mirdametinib;” “(640.105) Nerandomilast;” H. B. 1329 -2- LC 65 0071 “(644.605) Nipocalimab-aahu;” “(663.65) Onasemnogene abeparvovec-brve;” “(681.65) Paltusotine;” “(698.5) Penpulimab-kcqx;” “(742.7) Plozasiran;” "(768.6) Prademagene zamikeracel;" "(832.975) Remibrutinib;" "(836.6) Revakinagene taroretcel-lwey;" “(842.3) Rilzabrutinib;” "(852.055) Sebetralstat;" "(855.1) Sepiapterin;" "(855.735) Sevabertinib;" "(855.83) Sibeprenlimab-szsi;" "(927.8) Sunvozertinib;" “(929.7) Suzetrigine;” "(930.978) Taletrectinib;" "(931.565) Telisotuzumab vedotin-tllv;" “(974.65) Treosulfan;” "(1030.9) Vimseltinib;" "(1042.2) Ziftomenib;" “(1042.85) Zoliflodacin;” "(1042.91) Zongertinib;" “(1042.93) Zopapogene imadenovec-drba;” SECTION 3. Said chapter is further amended in subsection (b) of said Code section by repealing and reserving paragraph (324) and by revising paragraphs (60.3), (160.5), and (217.2) as follows: H. B. 1329 -3- LC 65 0071 “(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;” "(160.5) Chikungunya vaccine, Live;" "(217.2) COVID-19 Vaccine, mRNA;" SECTION 4. Said chapter is further amended in subsection (c) of said Code section by revising paragraph (9.33) as follows: "(9.33) Epinephrine , : (A) When when used in a device that delivers a metered spray of 0.125 mg. of epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA); and (B) When distributed by a pharmacist as provided by the State Board of Pharmacy, in a device that delivers a spray of 2 mg. of epinephrine or less to provide emergency treatment of allergic reactions, including anaphylaxis, and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA);" SECTION 5. This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval. SECTION 6. All laws and parts of laws in conflict with this Act are repealed. H. B. 1329 -4-

Instrument

Schedule I: hallucinogenic substances

Source

https://gdna.georgia.gov/document/document/132824956ocga-16-13-controlled-substancespdf/download

Retrieved

2026-10-31

Fingerprint

7286c1aadfc08d89

   (3) Any material, compound, mixture, or preparation which contains any quantity of the
following hallucinogenic substances, their salts, isomers (whether optical, position, or
geometrics), and salts of isomers, unless specifically excepted, whenever the existence of
these salts, isomers, and salts of isomers is possible within the specific chemical

designation:

      (A) 3, 4-methylenedioxyamphetamine;

      (B) 5-methoxy-3, 4-methylenedioxyamphetamine;

      (C) 3, 4, 5-trimethoxyamphetamine;

      (D) Bufotenine;

      (E) Diethyltryptamine;

      (F) Dimethyltryptamine;

      (G) 4-methyl-2, 5-dimethoxyamphetamine;

      (H) Ibogaine;

      (I) Lysergic acid diethylamide;

      (J) Mescaline;

      (K) Peyote;

      (L) N-ethyl-3-piperidyl benzilate;

      (M) N-methyl-3-piperidyl benzilate;

      (N) Psilocybin;

      (O) Psilocyn (Psilocin);

      (P) Tetrahydrocannabinols which shall include, but are not limited to:

         (i) All synthetic or naturally produced samples containing more than 15 percent by
weight of tetrahydrocannabinols; and

         (ii) All synthetic or naturally produced tetrahydrocannabinol samples which do not
contain plant material exhibiting the external morphological features of the plant
cannabis;

      (Q) 2, 5-dimethoxyamphetamine;

      (R) 4-bromo-2, 5-dimethoxyamphetamine;

      (S) 4-methoxyamphetamine;

      (T) Cyanoethylamphetamine;

      (U) (1-phenylcyclohexyl) ethylamine;

      (V) 1-(1-phenylcyclohexyl) pyrrolidine;

      (W) Phencyclidine;

      (X) 1-piperidinocyclohexanecarbonitrile;

      (Y) 1-phenyl-2-propanone (phenylacetone);

      (Z) 3, 4-Methylenedioxymethamphetamine (MDMA);

      (AA) 1-methyl-4-phenyl-4-propionoxypiperidine;

      (BB) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine;

      (CC) 3-methylfentanyl;

      (DD) N-ethyl-3, 4-methylenedioxyamphetamine;

      (EE) Para-flurofentanyl;

      (FF) 2,5-Dimethoxy-4-Ethylamphetamine;

      (GG) Cathinone;

      (HH) MPPP (1-Methyl-4-Phenyl-4-Propionoxypiperidine);

      (II) PEPAP (1-(2-phenethyl)-4 phenyl-4-acetoxypiperide);

      (JJ) Alpha-Methylthiofentanyl;

      (KK) Acetyl-Alpha-Methylfentanyl;

      (LL) 3-Methylthiofentanyl;

      (MM) Beta-Hydroxyfentanyl;

      (NN) Thiofentanyl;

      (OO) 3,4-Methylenedioxy-N-Ethylamphetamine;

      (PP) 4-Methylaminorex;

      (QQ) N-Hydroxy-3,4-Methylenedioxyamphetamine;

      (RR) Beta-Hydroxy-3-Methylfentanyl;

      (SS) Reserved;

      (TT) N, N-Dimethylamphetamine;

      (UU) 1-(1-(2-thienyl)cyclohexy)pyrrolidine;

      (VV) 4-Bromo-2,5-Dimethoxyphenethylamine (DMPE);

      (WW) Alpha-Ethyltryptamine;

      (XX) Methcathinone;

      (YY) Aminorex;

Instrument

Schedule I -- Hallucinogens (Georgia Board of Pharmacy scheduling rule placing 5-MAPB under O.C.G.A. 16-13-25(3))

Source

https://rules.sos.ga.gov/gac/480-34-.07

Retrieved

2026-07-20

Fingerprint

536dedc5bafa1575

(1) This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, including any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers under Schedule I of the Georgia Controlled Substances Act, Section 16-13-25(3) as follows: (BBBB) Methoxyphencyclidine (MeO-PCP); (CCCC) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MiPT); (DDDD) N,[ALPHA]-dimethyl-5-benzofuranethanamine (5-MAPB); (EEEE) 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (SDB-006); (FFFF) methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA). (2) This rule is based on the following findings of the Board: (a) that hallucinogens have an extremely high potential for abuse; (b) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances; (c) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation; (d) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds; (e) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act; and (f) that these compounds have no known precursor already scheduled under the Act.

Instrument

Schedule III

Source

https://gdna.georgia.gov/document/document/132824956ocga-16-13-controlled-substancespdf/download

Retrieved

2026-10-31

Fingerprint

c636a6dd63cac41b

§ 16-13-27. Schedule III


 The controlled substances listed in this Code section are included in Schedule III:

  (1) Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances, included as having a stimulant effect on the central nervous system, including
its salts, isomers (whether optical, position, or geometric), and salts of such isomers
whenever the existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation:

    (A) Those compounds, mixtures, or preparations in dosage unit forms containing any
stimulant substances which are listed as excepted compounds by the State Board of
Pharmacy pursuant to this article, and any other drug of quantitative composition so
excepted or which is the same except that it contains a lesser quantity of controlled
substances;

   (B) Benzphetamine;

   (C) Chlorphentermine;

   (D) Clortermine;

   (E) Phendimetrazine;

  (2) Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of the following
substances included as having a depressant effect on the central nervous system:

    (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
pentobarbital, or any salts thereof and one or more active medicinal ingredients which are
not listed in any schedule;

    (B) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital,
or any salt of any of these drugs and approved by the State Board of Pharmacy for
marketing only as a suppository;

   (C) Any substance which contains any quantity of a derivative of barbituric acid or
any salt thereof;

   (D) Chlorhexadol;

   (E) Reserved;

   (F) Lysergic acid;
   (G) Lysergic acid amide;

   (H) Methyprylon;

   (I) Sulfondiethylmethane;

   (J) Sulfonethylmethane;

   (K) Sulfonmethane;

   (L) Tiletamine/Zolozepam (Telazol);

 (3) Nalorphine;

  (4) Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture, or preparation containing limited quantities of the following narcotic
drugs, or any salts thereof:

    (A) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not
more than 90 milligrams per dosage unit, with an equal or greater quantity of an
isoquinoline alkaloid of opium;

    (B) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not
more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts;

    (C) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its
salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold
or greater quantity of an isoquinoline alkaloid of opium;

    (D) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its
salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more
active, nonnarcotic ingredients in recognized therapeutic amounts;

    (E) Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters
or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts;

    (F) Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100
milliliters or not more than 15 milligrams per dosage unit, with one or more active,
nonnarcotic ingredients in recognized therapeutic amounts;

    (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or
not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts;
    (H) Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or
per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts;

  (5) The State Board of Pharmacy may except by rule any compound, mixture, or
preparation containing any stimulant or depressant substance listed in paragraphs (1) and
(2) of this Code section from the application of all or any part of this article if the
compound, mixture, or preparation contains one or more active, medicinal ingredients not
having a stimulant or depressant effect on the central nervous system, and if the
admixtures are included therein in combinations, quantity, proportion, or concentration
that vitiate the potential for abuse of the substances which have a stimulant or depressant
effect on the central nervous system;

  (6) Any anabolic steroid or any salt, ester, or isomer of a drug or substance described or
listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Such term
does not include an anabolic steroid which is expressly intended for administration
through implants to cattle or other nonhuman species and which has been approved by
the secretary of health and human services for such administration:

   (A) Boldenone;

   (B) Chlorotestosterone;

   (C) Clostebol;

   (D) Dehydrochlormethyltestosterone;

   (E) Dihydrotestosterone;

   (F) Drostanolone;

   (G) Ethylestrenol;

   (H) Fluoxymesterone;

   (I) Formebolone;

   (J) Mesterolone;

   (K) Methandienone;

   (L) Methandranone;

   (M) Methandriol;
    (N) Methandrostenolone;

    (O) Methenolone;

    (P) Methyltestosterone;

    (Q) Mibolerone;

    (R) Nandrolone;

    (S) Norethandrolone;

    (T) Oxandrolone;

    (U) Oxymesterone;

    (V) Oxymetholone;

    (W) Stanolone;

    (X) Stanozolol;

    (Y) Testolactone;

    (Z) Testosterone;

    (AA) Trenbolone;

  (7) Ketamine;

 (8) Dronabinol (synthetic) in sesame oil and encapsulated in a U.S. Food and Drug
Administration approved drug product also known as Marinol;

  (9) Sodium oxybate, when the FDA approved form of this drug is in a container labeled
in compliance with subsection (a) or (b) of Code Section 26-3-8, in the possession of a
registrant permitted to dispense the drug, or in the possession of a person to whom it has
been lawfully prescribed;

  (10) Buprenorphine.

Instrument

Sale, distribution, or possession of dangerous drugs

Source

https://gdna.georgia.gov/document/document/132824956ocga-16-13-controlled-substancespdf/download

Retrieved

2026-10-31

Fingerprint

78767b19f5beddfd

§ 16-13-72. Sale, distribution, or possession of dangerous drugs

  Except as provided for in this article, it shall be unlawful for any person, firm,
corporation, or association to sell, give away, barter, exchange, distribute, or possess in
this state any dangerous drug, except under the following conditions:

  (1) A drug manufacturer, wholesaler, distributor, or supplier holding a license or
registration issued in accordance with the Federal Food, Drug, and Cosmetic Act and
authorizing the holder to possess dangerous drugs may possess dangerous drugs within
this state but may not distribute, sell, exchange, give away, or by any other means supply
dangerous drugs without a permit issued by the State Board of Pharmacy. Any drug
manufacturer, wholesaler, distributor, or supplier holding a permit issued by the State
Board of Pharmacy may sell, give away, exchange, or distribute dangerous drugs within
this state, but only to a pharmacy, pharmacist, a practitioner of the healing arts, and
educational institutions licensed by the state, or to a drug wholesaler, distributor, or
supplier, and only if such distribution is made in the normal course of employment;

 (2) A pharmacy may possess dangerous drugs, but the same shall not be sold, given
away, bartered, exchanged, or distributed except by a licensed pharmacist in accordance
with this article;

  (3) A pharmacist may possess dangerous drugs but may sell, give away, barter,
exchange, or distribute the same only when he compounds or dispenses the same upon
the prescription of a practitioner of the healing arts. No such prescription shall be refilled
except upon the authorization of the practitioner who prescribed it;

 (4) A practitioner of the healing arts may possess dangerous drugs and may sell, give
away, barter, exchange, or distribute the same in accordance with Code Section 16-13-74;

  (4.1) A physician in conformity with Code Section 43-34-26.1 may delegate to a nurse
or a physician's assistant the authority to possess vaccines and such other drugs as
specified by the physician for adverse reactions to those vaccines, and a nurse or
physician's assistant may possess such drugs pursuant to that delegation; provided,
however, that nothing in this paragraph shall be construed to restrict any authority of
nurses or physician's assistants existing under other provisions of law;

  (4.2) A registered professional nurse licensed under Article 1 of Chapter 26 of Title 43
who is employed or engaged by a licensed home health agency may possess sterile saline,
sterile water, and diluted heparin for use as intravenous maintenance for use in a home
health setting, and such nurse may administer such items to patients of the home health
agency upon the order of a licensed physician. The State Board of Pharmacy shall be
authorized to adopt regulations governing the storage, quantity, use, and administration of
such items; provided, however, nothing in this paragraph or in such regulations shall be
construed to restrict any authority of nurses existing under other provisions of law;

  (5) A manufacturer’s sales representative may distribute a dangerous drug as a
complimentary sample only upon the written request of a practitioner. The request must
be made for each distribution and shall contain the names and addresses of the supplier
and the requestor and the name and quantity of the specific dangerous drug requested.
The written request shall be preserved by the manufacturer for a period of two years; and

  (6) Such person, firm, corporation, or association shall keep a complete and accurate
record of all dangerous drugs received, purchased, manufactured, sold, dispensed, or
otherwise disposed of and shall maintain such records for at least two years or in
conformance with any other state or federal law or rule issued by the Georgia State Board
of Pharmacy.

Instrument

Violations of the Dangerous Drug Act

Source

https://www.legis.ga.gov/api/legislation/document/20152016/162303

Retrieved

2026-10-31

Fingerprint

f4b84b65c2bd33cf

16-13-79.
(a) Except as provided in subsections (b), (c), and (d) of this Code section, any person who violates this article shall be guilty of a misdemeanor.
(b) Any person who distributes or possesses with the intent to distribute nitrous oxide for any use other than for a medical treatment prescribed by the order of a licensed medical practitioner, except as provided for by paragraph (16) of subsection (c) of Code Section 16-13-71, shall be guilty of a felony and upon conviction thereof shall be punished by imprisonment for not less than one year nor more than three years or by a fine not to exceed $5,000.00 or both.
(c) Any person who distributes or possesses with the intent to distribute to any person under 18 years of age nitrous oxide for any use other than for a medical treatment prescribed by the order of a licensed medical practitioner, except as provided for by paragraph (16) of subsection (c) of Code Section 16-13-71, shall be guilty of a felony and upon conviction thereof shall be punished for not less than two years nor more than six years or by a fine not to exceed $10,000.00 or both.
(d) This article shall not apply to any person who possesses, distributes, sells, or uses nitrous oxide for food preparation in a restaurant, for food service, or in household products.
(e) Any person who knowingly distributes or resells any nonprescription injectable insulin product which was first obtained through an over-the-counter sale made to a patient from any pharmacy, practitioner, or other source shall be guilty of a misdemeanor. All such injectable insulin distributed or sold in this manner is considered to be an adulterated dangerous drug and unsalable, making it subject to seizure under the laws of this state.

Instrument

Establishment of schedules

Source

https://gdna.georgia.gov/document/document/132824956ocga-16-13-controlled-substancespdf/download

Retrieved

2026-11-01

Fingerprint

cb80e3a7510e958e

(a) There are established five schedules of controlled substances, to be known as 
Schedules I, II, III, IV, and V. The schedules shall consist of the substances listed in 
Code Sections 16-13-25 through 16-13-29. The schedules so established shall be updated 
and republished by the State Board of Pharmacy on an annual basis.